Influenza A viruses (IAVs) encode their genome as eight negative sense RNA segments. 34
Introduction 75 76
Influenza virus infections represent a substantial global burden on human health. Each 77 year, it is estimated that influenza viruses cause up to 5 million severe infections globally, 78 resulting in up to 645,000 mortalities [1, 2] . In 2018, patient care and productivity loss due 79 to influenza infection cost an estimated $11.2 billion in the U.S. alone [3] . Influenza A 80 viruses (IAVs), the major contributor to total human influenza disease, possess a 81 segmented genome consisting of eight discrete, negative-sense viral RNAs (vRNAs) [4] . 82
Each of the eight vRNA segments consist of terminal 5' and 3' untranslated regions (UTRs) 83
flanking an internal open-reading frame that encodes that one or maximally two viral 84
proteins [5] . The UTRs, as well as the proximal portions of the coding regions, form 85 "packaging signals" that are both necessary and sufficient for incorporation of each vRNA 86 into progeny virions [6] [7] [8] [9] [10] [11] . Although the underlying mechanisms that control packaging 87 are incompletely understood, it has been hypothesized that segments may potentially 88 interact with one another via vRNA-vRNA interactions across genome segments [12] [13] [14] [15] [16] . 89
In any case, experimental evidence has supported the theory that non-random genome 90 packaging controls the proper incorporation of segments into progeny virions [17, 18] . 91
The segmented nature of the viral genome, and at least some intra-strain conserved 92 regions of the packaging signals, allows for reassortment to occur between strains that 93 have coinfected the same host cell [19] . The process of genetic reassortment, termed 94 antigenic shift, can lead to the development of novel strains and can cause pandemic 95 outbreaks, such as the one that occurred in 2009 with the H1N1 pandemic "swine" flu 96
virus [20] . 97 the two viruses would lead to the production of non-viable particles and thus halt viral 167 spread. In this report, we describe the generation of a live attenuated, 10-segmented 168
(10S) influenza virus that accomplishes this goal. Administration of 10S viruses either 169
prophylactically or therapeutically rescued animals from an otherwise lethal viral infection. 170
Since the highly conserved, strain independent process of viral assembly is the target of 171 this approach, we predict that it will be difficult or even impossible for IAV to generate 172 functional escape variants through acquisition of random mutations. 173
174

Results
176
Evaluation of viral genetic manipulations capable of generating 9-segmented IAVs 177
We were interested in generating influenza viruses that could be genetically programmed 178 to harbor artificial genomic segments that would interfere with the correct packaging of 179 genome segments into nascent virions. It was previously reported that the NA packaging 180 signals could be duplicated and utilized to package a ninth genomic segment [51] . While 181 this approach was utilized to encode additional antigens as a vaccine platform, we 182 theorized that this and similar approaches could be utilized to generate viruses harboring 183 artificial, interfering segments. We therefore tested the ability to duplicate various 184 packaging signals and generate 9-segmented viruses. We tested: NA, NP, HA, and PA 185 duplicated packaging signals harboring different viral proteins in different combinations 186 (Table 1) . In all cases, the "9 th " segment (Supplementary Figure 1) was designed with 187 unique packaging signals so that it would always be packaged, but failure to package the 188 duplicated packaging signal segment would lead to the loss of an essential viral protein.
189
The 9 th segment always encoded super-folder GFP (sfGFP) or mCherry. Surprisingly, 190 very few segment duplications were amenable to this approach. As previously reported, 191 duplication of the NA packaging signal is tolerated, but of everything else tested, only 192 duplication of the PA packaging signal was tolerated (Table 1) . 193
194 Additionally, we also tested the potential of using splice sites in the 7th and 8th segments 195 of IAV to generate 9S viruses expressing either M1 or NS1 in the ninth segment and a 196 fluorescent protein with M2 or NEP in segment 7 or 8, respectively (Table 1 in MDCK cells, demonstrated that while both of these viruses exhibit attenuated levels of 213 growth ( Figure 1C ), they do successfully package and propagate the artificial segment 214 ( Figure 1D ). We hypothesized that the decreased viral growth may be due to the viruses 215 only packaging one of the segments that harbors the duplicated packaging signal. If this 216
were the case, we would expect to observe a large number of defective, 8 segmented 217
viruses lacking an essential viral protein. In order to test this, we grew the viruses in 218 embryonated chicken eggs and measured infectious particles via plaque assay, and we 219 also performed a hemagglutinin (HA) assay, which measures both infectious and 220 noninfectious particles ( Figure 1E,F) . Again, we observed a dramatic reduction in viral 221 titer, however the magnitude of the observed defect in the HA assay was much smaller. 222
To represent this difference, we calculated the "Relative DI units" of our 9S viruses, 223 relative to WT virus, with WT set at an arbitrary value of 1, by dividing HA units by the 224 endpoint titer ( Figure 1G ). As expected, the 9S PB1 mCherry virus produced ~10 2 times 225 more non-viable progeny than did the WT PR8 virus, while the 9S PB2 sfGFP virus 226 produced ~10 3 times more non-viable progeny than did WT PR8 ( Figure 1G ). Thus, both 227 9S viruses produced a significantly higher ratio of non-viable to viable virions than WT 228 PR8 virus, and that ratio was, to some extent, dictated by which viral segment had been 229
duplicated. 230 231
We next wanted to assess how a 9 th segment affected the virulence of the virus, as well 232 as assay the ability of the two 9S fluorescent viruses to modulate influenza disease. To 233 determine if the addition of the 9 th segment attenuated the virus, LD50 experiments were 234 performed in immunocompetent C57BL/6 mice. Wild-type PR8 virus was found to be 235 lethal at all doses tested, killing all infected mice with as little as 10 PFU (Figures 2A,D) . 236
The two 9S viruses, however, were significantly attenuated relative to the parental virus. 237
The 9S PB1 mCherry virus required 10 4 PFU for lethality and 10 2 PFU treated animals 238 showed no death or weight loss ( Figure 2B,E) . Similarly, the 9S PB2 sfGFP caused lethal 239 disease at a dose of 10 4 PFU and 10 2 PFU treated animals exhibited no death or weight 240 loss ( Figure 2C,F) . The attenuation of the 9S viruses suggested that these viral genomic 241 designs may fit the criteria of a live-attenuated therapeutic. We therefore assessed the 242 capability of each 9-segmented fluorescent virus to interfere with a lethal challenge of WT 243 PR8. For this initial test, we coinfected animals with 20 PFU of WT virus in combination 244 with 500 PFU of either the 9S PB1 mCherry or the 9S PB2 sfGFP virus and monitored 245 animals for body weight loss for 14 days post-infection ( Figure 2G ). 500 PFU of the 9S 246 viruses was chosen as the highest dose that would not be expected to induce any clinical 247 disease. Non-treated control animals rapidly lost body weight and succumbed to the 248 challenge, as expected ( Figure 2H, 2K) . Administration of the 9S PB1 mCherry virus 249 caused a measurable protective effect, with treated animals experiencing an ~48 hour 250 delay in the onset of body weight loss when compared to the lethal WT PR8 challenge 251 ( Figure 2I ). Moreover, 25% of coinfected animals survived and recovered from this 252 normally lethal challenge with WT PR8 ( Figure 2L ). In contrast, the 9S PB2 sfGFP virus 253 did not cause treated animals to display any statistically significant reduction in weight 254 loss or increased survival compared to the lethal WT PR8 challenge alone ( Figure 2J , 255
2M). 256 257
The artificial viral segment size is not correlated with therapeutic effect 258
While the 9S PB1 mCherry virus did offer some therapeutic effect, the effect size was 259 minimal. We hypothesized that this was likely due to the design of our segment. During 260 normal WT replication, DI segments arise from the large scale deletion of ORFs, often 261 reducing the size of a DI segment to a total of less than 500 nucleotides. This significant 262 reduction in size causes the DI segment to be replicated much faster than the full-length 263 WT segment, drastically enhancing the chance that the DI segment is packaged into a 264 progeny virion over the WT one. Our artificial segments, however, were actually larger 265 than a standard DI segment, potentially reducing the efficacy of this strategy. In order to 266 determine if the protective effect of a 9S virus could be augmented by making it more like 267 a DIP, we designed a DI-like oligonucleotide to replace PB1 mCherry, based on a 268 previously characterized PB1 DI segment reported by Saira et al.
[38] ( Figure 3A ). We 269 chose to focus on the PB1-mCherry segment as this segment showed a larger degree of 270 protection from challenge relative to the PB2-sfGFP segment. We used the PB1 DI 271 segment was in place of the mCherry expressing segment to generate a virus harboring 272 a more DI-like segment ( Figure 3B ). The 9S PB1 DI virus again was attenuated relative 273 to WT viruses by approximately the same magnitude as the other 9S viruses ( Figure 3C ). 274
Analysis of titer and HA units after growth in chicken eggs revealed that similarly to the 275 other 9S viruses, the 9S PB1 DI virus produced roughly 10 2 times more non-viable 276 progeny than WT PR8 virus ( Figure 1D-F) . 277
278
As expected, the 9S PB1 DI virus was significantly attenuated in vivo, even more so than 279 the previous 9S viruses. Only the highest dose tested, 10 4 PFU, was lethal, whereas the 280 other two doses, 10 3 and 10 2 PFU, caused no death or weight loss ( Figure 3G -H). To 281 test the protective efficacy of the 9S DI virus, we simultaneously treated mice with 500 282 PFU of the DI virus together with a normally lethal dose of WT PR8. Similar to the 9S PB1 283 mCherry virus, the 9S PB1 DI virus was found to confer a protective effect, with weight 284 loss occurring 24 hours later than seen in the control, WT PR8 challenged mice, and an 285 increase in survival rates ( Figure 3I,J) . Thus, the 9S PB1 DI virus had a very similar 286 protective effect to the 9S PB1 mCherry virus, suggesting that the ability of these viruses 287 to interfere with influenza disease is independent of the artificial genome segment size. Since the size of the DI segment did not appear to play a critical role in interfering with 292 viral replication/packaging, we hypothesized that potentially increasing the number of 293 segments would increase the ability of the virus to interfere with WT viral spread. Given 294 that we able to successfully utilize two 9S genome packaging strategies, that utilized 295 distinct packaging signal duplications, to generate two different viable 9S IAV variants, 296
we considered the possibility of combining the two to generate a viable 10S IAV. Indeed, 297 these two strategies were compatible, and we were successful in rescuing a 10S IAV 298 harboring 6 WT segments alongside four genetically manipulated ones ( Figure 4A) . 299
Growth curve analysis of the 10S virus shows it is extremely attenuated, even more than 300 the 9S viruses ( Figure 4B ). A fluorescent microscopy time course of the 10S virus 301 revealed that virus indeed functionally co-packaged both of the fluorescent artificial 302 segments at all timepoints ( Figure 4C ). Analysis of viral titer and HA units after growth in 303 chicken eggs demonstrated that the 10S virus, while highly attenuated, produced a 304 significantly higher ratio of nonviable progeny, nearly 10 3 times higher than WT PR8 virus 305 ( Figure 4D-F) . 306 307 Next, we assessed the virulence of the 10S virus via an LD50 experiment in C57BL/6 308 mice. The virus was highly attenuated; animals infected with doses as high as 10 4 PFU, 309 which caused mortality when using any of the 9S viruses, experienced no detectable 310 decline in body weight and all survived ( Figure 5A-B) . This increased attenuation is highly 311 desirable when considering its use as a potential antiviral therapeutic. We were 312 concerned, however, that this attenuated replication level would be too low to 313 demonstrate any protective efficacy against WT IAV. As an initial test of the potential 314 efficacy of a 10S virus as an antiviral agent, we challenged C57BL/6 mice with 20 PFU of 315 WT PR8 virus in combination with 5000 PFU of the 10S virus ( Figure 5C ). 316
Remarkably, animals infected with both WT PR8 virus and 10S virus exhibited no 317 detectable weight loss, whereas WT PR8 only infected control animals began to lose body 318 weight as early as 5 days post-infection ( Figure 5D ). All of the 10S treated animals 319 survived the infection, whereas all of the WT PR8 only infected animals succumbed 320 ( Figure 5E ). We were next curious to assess 10S virus efficacy in more authentic 321 therapeutic application. We therefore infected mice with a lethal dose of 20 PFU of WT 322 PR8 virus, administered the 10S therapeutic dose 24 hours later, and then monitored 323 animals for weight loss for 14 days post-infection ( Figure 5F ). While the 10S virus 324 treatment 24 hours after WT infection was not as effective as a simultaneous coinfection, 325
we did observe a significant reduction in weight loss of the 10S treated animals, when 326 compared to animals infected with WT PR8 alone ( Figure 5G ). Furthermore, animals that 327 were administered the 10S virus at 24 hours after WT PR8 infection had a significantly 328 increased survival rate, 25% mortality versus 100% mortality, when compared to control 329 WT PR8 only infected animals ( Figure 5H) This research was initially started with the goal of creating a replication competent, live 337 attenuated virus that would be able to encode genomic segments capable of disrupting 338 effective genomic packaging of a co-infecting WT virus. Our approach is mechanistically 339 distinct from naturally occurring DI particles, which are naturally generated via large 340 deletions of a viral segment. The 10S platform however, essentially mimics the concept 341 of facilitating packaging of a defective viral segment, which then leads to the release of 342 virions bearing incomplete viral genomes. In order to produce this virus, we first verified 343 that a previously published approach of duplicating the NA segment packaging signals 344 could be utilized to make the virus encode a 9 th genomic segment [51]. We next 345
expanded upon that work and tested a variety of other genomic organizations and found 346 that only rare combinations of viral genes and packaging signals were able to be tolerated 347 by the virus. There are probably a number of constraints that underlie this phenomenon. 
to be dispensable, yet we were unable to rescue a virus with duplicated NS packaging 361 signals (Table 1) . This discrepancy may be explained by the fact that the levels of 362 transcription and translation of these viral segments is controlled by motifs in these 363 specific segments [53, 54] , and thus the combination of different viral ORFs and 364 packaging signals leads to a disruption of the normal controllers of viral 365 transcription/translation rates, negatively impacting viral fitness. This concept is 366 somewhat supported by our data that a virus encoding the PB2 protein flanked by NP 367 packaging signals is non-viable; NP is expressed in cells to a much higher level than PB2. 368
When we encoded PB2 flanked by PA packaging signals however, the virus was viable, 369
and PA and PB2 levels in the infected cell are reasonably similar [55] . 370
371
To our knowledge, 9S viruses had never previously been tested for their ability to interfere 372 with IAV disease progression, and we therefore decided to test our 9S viruses in that 373 capacity. We chose to administer these viruses at the time of infection with a lethal dose 374 of WT virus as a reasonably stringent test for potential efficacy of the approach. 375 Disappointingly, only one of our 9S viruses displayed any protective efficacy, and the 376 effect was limited. In order to try and improve the ability of our artificial viral segments to 377 titrate viral RdRPs away from WT genomic segments, we made the artificial segment 378 much smaller. Naturally occurring defective interfering viral segments are much smaller 379 than our fluorescent protein encoding artificial 9 th segments, and we therefore generated 380 a 9S virus harboring a segment that was more similar in size to naturally occurring DI 381 segments [38]. While we were able to generate viruses that harbored these DI like 382 segments, we found that the reduction in segment size led to very little, if any, 383 improvement in efficacy. Although these insights are derived from a highly artificial 384 system, our data suggest that it may be interesting to reevaluate the relative importance 385 of segment length in the context of naturally occurring DI particles. 386
387
Since varying the artificial segment size was not correlated with protection from IAV, we 388 hypothesized that the efficacy of our approach was instead dependent on the efficiency 389 of packaging of our artificial genome segments by WT viruses, leading to progeny virions 390 with incomplete genomes. Were that the case, making a virus which encoded more 391 artificial segments could potentially confer higher protective efficacy. We therefore 392 produced a 10S IAV that possessed 2 artificial genome segments instead of 1. Since our 393 two validated genetic approaches were compatible with each other (i.e. different 394 segments and packaging signals were utilized in the two approaches), we attempted to 395 combine our 9s PB1 mCherry and 9s PB2 sfGFP virus strategies to produce a 10S virus. 396
This effort was successful, resulting in the first known report of a stable 10S IAV. Although 397 the growth rates of 10S viruses were significantly reduced relative to both WT and 9S 398 viruses, the protective effect observed was far superior to that seen with any of the 9S 399 viruses. When administered at the same time of infection, 100% of our treated mice 400 survived a normally lethal dose of WT PR8 while exhibiting no detectable weight loss. 401
While the effect of truly therapeutic administration 24 HPI had a less striking effect, we 402 were still able to significantly delay the onset of clinical symptoms and reduce mortality 403 rates by up to 75%. 
Materials and Methods 453
Ethics Statement 454
All procedures were carried out in compliance with the Duke University IACUC approved 455 protocol number A189-18-08. Duke University maintains an animal program that is 456 currently registered with the USDA, assured through the NIH/PHS, and accredited by 457 AAALAC International. Animals were monitored daily for the following: respiratory rate, 458 ambulating difficulty, ruffled fur, lack of grooming, restlessness, reluctance to move, and 459 bodyweight loss. Humane endpoints were primarily based on bodyweight loss, and 460 defined as ³ 20% of the starting bodyweight. The primary euthanasia method used was 461 
Animal Infections 467
Eight to 10-week-old C57BL/6 mice were purchased from Jackson Laboratories and 468 maintained at Duke University animal facilities. For all experiments, a sample size of at 469 least 4 mice per group were used. Prior to infection, mice were anesthetized with a 100-470 microliter injection of a ketamine-xylazine mixture. Mice were weighed and tail-marked, 471 and 40 microliters of virus diluted in pharmaceutical-grade PBS was administered 472 intranasally. Mice were weighed daily and euthanized once the predetermined humane 473 endpoint was reached. Therapeutic doses of 9S and 10S half were ½ of the highest 474 dose that caused only mild disease in mice when administered alone. 475
Cell Culture 477
Madin-Darby canine kidney (MDCK) cells, from the American Type Culture collection 478 (ATCC), were grown in minimal essential medium (MEM) supplemented with 10% fetal 479 bovine serum, HEPES, NaHCO3, GlutaMAX, and penicillin-streptomycin. Human 480 embryonic kidney 293T cells (from the ATCC) were grown in Dulbecco's modified Eagle's 481 medium (DMEM) supplemented with 10% fetal bovine serum, GlutaMAX, and penicillin-482 streptomycin. All cells were cultivated at 37ºC, at a 5% CO2 content, in the humidity 483 controlled Heracell TM VIOS 160i Thermo Scientific incubators. 484
485
Cloning and rescue of 9s and 10s viruses 486
Recombinant influenza viruses were generated as previously described by use of the 487 ambisense pDZ rescue plasmid system [63] . The 9s PB1 mCherry segment was 488 generated similarly to the construct described in Rescue supernatant was collected after 24 hours of incubation, with 200 microliters 538 injected into 10-day-old chicken eggs. Eggs were allowed to incubate virus for 72 hours 539 prior to collection of allantoic fluid. Viruses were purified via plaquing in MDCK cells and 540 subsequent amplification in chicken eggs. Stocks of concentrated 10s virions were 541 prepared using a 30% sucrose cushion for 1 h at 25,700 rpm on the Sorvall TH-641 542 swinging bucket rotor. 543
Viral titering 545
Allantoic fluid was collected from chicken eggs following infection, and viral titer was 546 determined via standard plaque assay procedures on MDCK cells. Briefly, cells were 547 incubated for 1 h in 500 microliters of diluted virus suspension at 37ºC, before removing 548 the virus and applying the agar overlay. Cells were then incubated at 37ºC for 72 h before 549 being fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for at least 550 4 h. The 4% PFA was then aspirated, and the agar layer was removed before washing 551 cells in PBS and incubating them at 4°C overnight in mouse serum from PR8-infected 552 mice. Mouse serum was diluted 1:2,000 in antibody dilution buffer, which was made using 553 The WT PR8 control was infected at an MOI of 0.05. Following the incubation period, the 585 infection medium was removed and cells were placed in complete medium supplemented 586 with 1:1000 diluted TPCK trypsin. At the indicated time after infection, MDCK cell medium 587 was removed and replaced with 1 ml of warm PBS. Cells were incubated with Hoechst 588 stain (1 microliter/ml of PBS) to allow for the staining of nuclei, and imaging was 589 
